TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6871776
Drug: Intraaortic protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraaortic protamine (3 mg . Kg‐1 injected over 30 sec)
Study: 6871776
Drug: Intravenous protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous protamine (3 mg . Kg‐1 injected over 30 sec)
Study: 30540966
Drug: Perioperative immunonutrition
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative immunonutrition (oral supplementation enriched with arginine, ω‐3 fatty acids, and dietary nucleotides)
Study: 24052490
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (2 mg/24 h) applied daily for 3 days
Study: 21909730
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D(3) 6,500 IU/day (20,000 IU twice per week + 800 IU/day)
Study: 21909730
Drug: Standard-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose vitamin D(3) 800 IU/day (placebo twice per week + 800 IU/day)
Study: 17956827
Drug: Once-daily LPV/r,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily LPV/r, tenofovir (TDF), and lamivudine (3TC)
Study: 15885349
Drug: IFN-alpha treatment
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha treatment without pre-emptive antidepressant therapy
Study: 9793810
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg/kg i.v.
Study: 11527130
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bisoprolol and Nifedipine
Study: 28806095
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections at 7 and 14 days post-surgery
Study: 22282958
Drug: IBN/SNAC formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBN/SNAC formulation co-administered with metformin
Study: 19761951
Drug: Group Interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Interpersonal Psychotherapy plus massage therapy (20 min sessions, once per week for 6 weeks)
Study: 10460375
Drug: Iodixanol (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (270 mg I/ml)
Study: 7599293
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone 0.2 IU
Study: 7599293
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone 0.7 IU
Study: 7599293
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone 0.02 IU
Study: 7599293
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone 2 IU
Study: 29526833
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose (MD) of ticagrelor (C-600 mg-24h)
Study: 29526833
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose (MD) of ticagrelor (C-600 mg-12h)
Study: 29526833
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d maintenance dose (C-75 mg-24h)
Study: 29526833
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily maintenance dose (T-90 mg twice daily)
Study: 25330838
Drug: Transcranial bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial bright light treatment via ear canals (1 lumen/0.72 mW/cm(2))
Study: 25330838
Drug: Transcranial bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial bright light treatment via ear canals (4 lumens/2.881 mW/cm(2))
Study: 25330838
Drug: Transcranial bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial bright light treatment via ear canals (9 lumens/6.482 mW/cm(2))
Study: 21108056
Drug: 800 ml
Normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 ml of 12.5% glucose solution the night before surgery and 200 ml two hours before surgery (Group A)
Study: 12357299
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg EPI/30 ml saline 19 times over 1 year (arm A)
Study: 12357299
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg EPI/30 ml 12 times over 5 months (arm B)
Study: 9796041
Drug: DTaP or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP or DTP vaccine
Study: 9796041
Drug: Pertactin value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertactin value < 7 EU ml‐1
Study: 9796041
Drug: Pertactin value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertactin value >= 7 EU ml‐1 and PT value >= 66 EU ml‐1
Study: 9796041
Drug: Pertactin value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertactin value >= 7 EU ml‐1 and PT value < 66 EU ml‐1
Study: 9796041
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antibody to pertactin, PT and fimbriae‐2
Study: 9796041
Drug: Multicomponent vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent vaccines containing pertactin and fimbriae
Study: 7636684
Drug: Rice-based oral
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based oral rehydration solution (50 g/L)
Study: 7636684
Drug: Glucose-based WHO/UNICEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based WHO/UNICEF solution
Study: 2613606
Drug: Ceftazidime (monotherapy)
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime (monotherapy)
Study: 2613606
Drug: Ceftazidime plus
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime plus tobramycin (combination therapy)
Study: 31669625
Drug: Anagliptin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagliptin (200 mg/day)
Study: 25627123
Drug: Split-thickness autograft
Normalized name: THICK & EASY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-thickness autograft combined with harvested skin cell suspension
Study: 17440685
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml flush of 5% povidone iodine (flush group)
Study: 8005548
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) plus ethinyl estradiol (EE)
Study: 23359581
Drug: Take Care
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL SPRAY [Take Care Clinic Instant Hand Sanitizer Spray]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Care technique (early surfactant treatment via thin catheter)
Study: 19395578
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg infliximab and 5 mg/kg infliximab
Study: 16984575
Drug: Wound gel
Normalized name: Hylase Wound Gel
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wound gel with gauze dressings
Study: 12764908
Drug: Tetramethylpyrazine (TMP)
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine (TMP) 3 mg/kg intravenously after anesthesia induction and 1 mg/kg in oxygenator during CPB
Study: 30096265
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (non-XPSG)
Study: 12127464
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient alcoholism treatment (ST)
Study: 12127464
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment (MT)
Study: 1693111
Drug: Otomize (neomycin/dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otomize (neomycin/dexamethasone spray)
Study: 28630183
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation
Study: 26423050
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL mepivacaine 1.5%
Study: 26423050
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL mepivacaine 1%
Study: 26423050
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL mepivacaine 1.5%
Study: 20934685
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment (n=17)
Study: 11369156
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg intravenous infusion over one hour)
Study: 11369156
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution intravenous infusion over one hour)
Study: 8988992
Drug: Propofol-based anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based anesthesia (5 mg.kg‐1.h‐1 prior to sternotomy, 3 mg.kg‐1.h‐1 thereafter)
Study: 30950283
Drug: Morning Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning Training (MG)
Study: 22766268
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human bone morphogenetic protein‐7 (rhBMP‐7) with deproteinised bone substitute (0.5 g)
Study: 22766268
Drug: deproteinised bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: deproteinised bone alone (2.0 g)
Study: 20147570
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg dDAVP combined with 10 µg hCRH
Study: 20147570
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg dDAVP combined with 30 µg hCRH
Study: 20147570
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg dDAVP alone
Study: 20147570
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg hCRH administered two hours after 10 µg dDAVP
Study: 20147570
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg dDAVP followed by 100 µg hCRH
Study: 11171729
Drug: IV combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV combination of diltiazem and digoxin
Study: 9603556
Drug: Presurgical orthopedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical orthopedic treatment (PSOT)
Study: 9603556
Drug: Non-presurgical orthopedic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-presurgical orthopedic treatment (non-PSOT)
Study: 15121648
Drug: Sertraline (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (both doses)
Study: 11698228
Drug: Protease Inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease Inhibitors (PI group)
Study: 3041555
Drug: Endoscopic injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injections of OK-432 plus systemic treatment (5-fluorouracil)
Study: 30782687
Drug: LDL-C reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C reduction to <120-160 mg/dL (group A)
Study: 30782687
Drug: LDL-C reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C reduction to <70 mg/dL (group B)
Study: 28087548
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (laser iridotomy followed by medical therapy and glaucoma surgery)
Study: 23142493
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate (MPH) 35 mg (approximately 0.5 mg/kg)
Study: 18481293
Drug: Corticosteroids administered
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids administered before biopsy
Study: 18481293
Drug: No corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroids administered before biopsy
Study: 15946237
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of niacinamide
Study: 7766741
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg b.d. for 7 days every month plus glucomannan 2 g/day
Study: 7766741
Drug: Placebo two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two tablets b.d. for 7 days every month plus glucomannan 2 g/day
Study: 12970233
Drug: Amiodarone (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (intravenous infusion for the first 24 hours at 1050 mg total, followed by oral therapy for 4 postoperative days at 4800 mg total)
Study: 29882203
Drug: Niclosamide (NCL)
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide (NCL) 1000 mg/day
Study: 29882203
Drug: Lactose (placebo)
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (placebo) 1000 mg/day
Study: 22630091
Drug: Dexamethasone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (single dose perioperative intravenous steroid)
Study: 22630091
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid (Control group)
Study: 20416042
Drug: TECNOB program
Approvals — FDA: no, EMA: no, PMDA: no
Description: TECNOB program (hospital-based intensive treatment for 1 month including diet therapy, physical training, and psychological counseling)
Study: 20416042
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (hospital-based treatment only)
Study: 12544638
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) supplementation (20 g/d for 5 days, then 3 g/d for 28 days)
Study: 6394514
Drug: Chlordiazepoxide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (200 mg daily for the first two days, then adjusted based on symptom relief)
Study: 6394514
Drug: Tiapride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (400 mg daily for the first two days, then adjusted based on symptom relief)
Study: 30470259
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (10 mg/kg) of liposomal amphotericin B (L-AmB) given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day)
Study: 30470259
Drug: Seven days
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven days of amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day) followed by seven days of fluconazole (1200 mg/day)
Study: 30470259
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (10 mg/kg) of L-AmB
Study: 10025892
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two target genes (TcRgamma and TcRdelta) for monitoring minimal residual disease (MRD)
Study: 2401249
Drug: ACC‐9653 (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC‐9653 (375 mg/5 ml; 232.87 mg free acid)
Study: 2401249
Drug: PHT sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT sodium (250 mg/5 ml; 229.95 mg free acid)
Study: 22319064
Drug: Abciximab administered
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab administered in the ambulance (ambulance group, n=127)
Study: 22319064
Drug: Abciximab administered
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab administered in the catheterization laboratory (hospital group, n=129)
Study: 17908370
Drug: Disease-modifying drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying drugs (DMDs)
Study: 15763392
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg per day for 4 weeks, then 10 mg per day for another 4 weeks)
Study: 1958007
Drug: Budesonide (BU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BU), 1200 micrograms daily, intranasally for 14 days
Study: 1958007
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BE), 400 micrograms daily, intranasally for 14 days
Study: 30916463
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment (for methadone-randomized individuals)
Study: 30916463
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment (for buprenorphine-randomized individuals)
Study: 22264303
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (10 grams with normal saline)
Study: 19172129
Drug: Galacto-oligosaccharides (GOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto-oligosaccharides (GOS) 5 g/L
Study: 9771245
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of inhaled steroids
Study: 7829006
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate (15 mg/kg per day) for a month
Study: 7525446
Drug: Post chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post chemotherapy GCSF
Study: 748987
Drug: Vaginal 15-methyl-PGF2alpha
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal 15-methyl-PGF2alpha methyl ester (3.0 mg)
Study: 748987
Drug: Intra-amniotic PGF2alpha
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic PGF2alpha (50 mg)
Study: 22507444
Drug: Placebo vibratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vibratory treatment (Control Group)
Study: 15782425
Drug: 7.5% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% CO2 inhalation for 20 min
Study: 15782425
Drug: Air inhalation
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air inhalation for 20 min
Study: 7582380
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (751 mg/l naringin)
Study: 6997537
Drug: KW-1062 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-1062 at 240 mg/day
Study: 6997537
Drug: KW-1062 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-1062 at 360 mg/day
Study: 6997537
Drug: KW-1062 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-1062 (both doses)
Study: 24592747
Drug: Tocotrienol-rich fraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol-rich fraction (TRF) of palm oil, 100 mg daily from early second trimester until delivery
Study: 22847319
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream products (three concentrations)
Study: 22847319
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel products (two concentrations)
Study: 22847319
Drug: Tretinoin (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin (same concentration) in different vehicles (gel vs. cream)
Study: 14962945
Drug: Subantimicrobial doses
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial doses of doxycycline (SDD) 20 mg twice daily
Study: 12166350
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg midazolam intramuscularly
Study: 12166350
Drug: No pre‐medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre‐medication
Study: 9856369
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg sustained-release indapamide
Study: 7596722
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for days 1 through 10, then amoxicillin for days 11 through 20
Study: 7596722
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for days 1 through 10, then amoxicillin-clavulanate for days 11 through 20
Study: 7596722
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for days 1 through 10, then placebo for either amoxicillin or amoxicillin-clavulanate for days 11 through 20
Study: 2229526
Drug: terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine 1% cream
Study: 2229526
Drug: placebo (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (cream vehicle)
Study: 873028
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptyline once daily
Study: 873028
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nortriptyline with 1-5 mg fluphenazine once daily
Study: 17396617
Drug: Oral trapidil
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trapidil (200 mg)
Study: 17396617
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (20 mg)
Study: 17396617
Drug: Intravenous trapidil
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trapidil (100 mg)
Study: 12085418
Drug: Verapamil SR/Trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil SR/Trandolapril 180/2 mg/day (VT)